2-(3-溴-5-甲酰基-4-羟基苯基)琥珀酸二甲酯 | 488713-18-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(3-溴-5-甲酰基-4-羟基苯基)琥珀酸二甲酯
• 英文名称: 2-(3-bromo-5-formyl-4-hydroxy-phenyl)-succinic acid dimethyl ester
• 英文别名: Dimethyl 2-(3-bromo-5-formyl-4-hydroxyphenyl)succinate；dimethyl 2-(3-bromo-5-formyl-4-hydroxyphenyl)butanedioate
• CAS: 488713-18-4
• 化学式: C₁₃H₁₃BrO₆
• 分子量: 345.147
• InChiKey: IAYUJVDECYBTLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  89.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(3-溴-5-甲酰基-4-羟基苯基)琥珀酸二甲酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 2-(3-甲酰基-4-((2-甲氧基乙氧基)甲氧基)-5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基)琥珀酸二甲酯
  参考文献：
  名称：

  Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model

  摘要：

  Highly selective and potent factor VIIa-tissue factor (fVIIa.TF) complex inhibitors were generated through structure-based design. The pharmacokinetic properties of an optimized analog (9) were characterized in several preclinical species, demonstrating pharmacokinetic characteristics suitable for once-a-day dosing in humans. Analog 9 inhibited platelet and fibrin deposition in a dose-dependent manner after intravenous administration in a baboon thrombosis model, and a pharmacodynamic concentration-response model was developed to describe the platelet deposition data. Results for heparin and enoxaparin (Lovenox) in the baboon model are also presented.

  DOI：

  10.1016/j.bmcl.2005.12.059
• 作为产物：
  描述：

  2-(4'-羟基苯基)丁烷-1,4-二酸 在 N-溴代丁二酰亚胺(NBS) 、 氯化亚砜 、 TEA 、 magnesium chloride 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 2-(3-溴-5-甲酰基-4-羟基苯基)琥珀酸二甲酯
  参考文献：
  名称：

  Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model

  摘要：

  Highly selective and potent factor VIIa-tissue factor (fVIIa.TF) complex inhibitors were generated through structure-based design. The pharmacokinetic properties of an optimized analog (9) were characterized in several preclinical species, demonstrating pharmacokinetic characteristics suitable for once-a-day dosing in humans. Analog 9 inhibited platelet and fibrin deposition in a dose-dependent manner after intravenous administration in a baboon thrombosis model, and a pharmacodynamic concentration-response model was developed to describe the platelet deposition data. Results for heparin and enoxaparin (Lovenox) in the baboon model are also presented.

  DOI：

  10.1016/j.bmcl.2005.12.059

文献信息

• 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
  申请人：Axys Pharmaceuticals, Inc.

  公开号：US20030114457A1

  公开（公告）日：2003-06-19

  The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

  本发明涉及新型因子VIIa、IXa、Xa、XIa的抑制剂，特别是因子VIIa，包括这些抑制剂的药物组合物，以及利用这些抑制剂治疗或预防血栓栓塞性疾病的方法。还公开了制备这些抑制剂的方法。
• [EN] 2-[5-(5-CARBAMIMIDOYL-1 H -HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS<br/>[FR] DERIVES DE 2-[5-(5-CARBAMIMIDOYL-1 H -HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-ACIDE SUCCINIQUE UTILISES COMME INHIBITEURS DU FACTEUR VIIA
  申请人：AXYS PHARM INC

  公开号：WO2003006011A1

  公开（公告）日：2003-01-23

  The present invention relates to novel inhibitors of formula (I) of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

  本发明涉及公式（I）的新型抑制剂，该抑制剂可抑制VIIa，IXa，Xa，XIa等因子，特别是VIIa，以及包含这些抑制剂的制药组合物，以及使用这些抑制剂治疗或预防血栓栓塞性疾病的方法。还公开了制备这些抑制剂的方法。
• 2-[5-(5-Carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-YL]-succinic acid derivatives as factor viia inhibitors
  申请人：Hu Huiyong

  公开号：US20050176797A1

  公开（公告）日：2005-08-11

  The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

  本发明涉及新型因子VIIa、IXa、Xa、XIa的抑制剂，尤其是因子VIIa，包括这些抑制剂的制药组合物，以及使用这些抑制剂治疗或预防血栓栓塞性疾病的方法。本发明还揭示了制备这些抑制剂的过程。
• Factor VIIa inhibitors: Improved pharmacokinetic parameters
  作者：Aleksandr Kolesnikov、Roopa Rai、Wendy B. Young、Joyce Mordenti、Liang Liu、Steven Torkelson、William D. Shrader、Ellen M. Leahy、Huiyong Hu、Erik Gjerstad、James Janc、Bradley A. Katz、Paul A. Sprengeler

  DOI：10.1016/j.bmcl.2006.01.037

  日期：2006.4

  Efforts to improve the potency and pharmacokinetic properties of small molecule factor VIIa inhibitors are described. Small structural modifications to existing leads allow the modulation of half-life and clearance, potentially making these compounds suitable candidates for drug development. (C) 2006 Elsevier Ltd. All rights reserved.
• Factor VIIa inhibitors: Gaining selectivity within the trypsin family
  作者：William D. Shrader、Aleksandr Kolesnikov、Jana Burgess-Henry、Roopa Rai、John Hendrix、Huiyong Hu、Steve Torkelson、Tony Ton、Wendy B. Young、Bradley A. Katz、Christine Yu、Jie Tang、Ronnel Cabuslay、Ellen Sanford、James W. Janc、Paul A. Sprengeler

  DOI：10.1016/j.bmcl.2005.12.040

  日期：2006.3

  Within the trypsin family of coagulation proteases, obtaining highly selective inhibitors of factor VIIa has been challenging. We report a series of factor Vila (fVIIa) inhibitors based on the 5-amidino-2-(2-hydroxy-biphenyl-3-yl)-benzimidazole (1) scaffold with potency for fVIIa and high selectivity against factors IIa, Xa, and trypsin. With this scaffold class, we propose that a unique hydrogen bond interaction between a hydroxyl on the distal ring of the biaryl system and the backbone carbonyl of fVIIa lysine-192 provides a basis for enhanced selectivity and potency for fVIIa. (C) 2005 Elsevier Ltd. All rights reserved.